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                                                        INTRODUCTION 
 
 
                       The recently published data on leprosy shows that the disease is in the final stages 
of elimination as a public health problem. The case load has fallen by around 90% in the past 2 
decades;1,2 the  number of countries with prevalence above elimination levels has fallen from 
122 in the mid eighties to just 9 at the beginning of 2005.3 At the national level, the disability 
rate is low,2,4 the New Case Detection Rate (NCDR) is showing a declining trend 4-11 and most 
importantly, India joined the ranks of countries which have achieved a prevalence rate of less 
than 1/10,000 population in December 2005.12 Integration of leprosy services into the general 
health services has been completed,13 with the resultant availability of early and appropriate 
medical care by adequately qualified and sufficiently trained physicians, to all patients in need of 
it, at  the first instance of approaching the health care system. 
 
                        In this context of elimination of leprosy and integration, and easy availability of 
leprosy services along with general health services, this study purports to look at the profile of 
patients from all over the country, seeking care at a tertiary care centre in South India.  We 
wanted to study their health seeking behavior, impairment and  disability status, activity 
limitation and  participation restriction. It would be interesting to know the disability rates in 
India, given the wide coverage of  multi drug therapy (MDT) and the low national disability 
rates.2,4 While disability rates at presentation would give us an idea of delays in case detection, 
so would development of new disabilities during or after treatment indicate presence of lacunae 
in presently available strategies for prevention of disabilities. The percentage of undiagnosed 
cases of leprosy among this population accessing a tertiary care centre would be an indication of 
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the patients not identified by the present health care system. The bacillary status of newly 
diagnosed patients, would give a rough idea of the levels of contagion in the community. The 
non economic burden of the disease has the following components – impairment, disability and 
handicap or participation restriction. The disability grade, Screening of Activity Limitation and 
Safety Awareness (SALSA) scale,14 Participation scale(P scale)15 and the General Health 
Questionnaire 12(GHQ 12) when considered together can be said to account for measurement of 
the non economic burden of disease.16 One published study is available on the SALSA,14 two on 
the P scale15,17 and several are in progress using both.  We wanted to evaluate the suitability of 
these two new scales, when used in a clinic based setting, for the assessment of activity and 
participation limitation, parameters very relevant even in the era of elimination and integration. 
 
                      This is an opportunity to study the experiences of patients with their disease and 
thus with the health care system in view of elimination and integration, and will give us insights 
that may help in the delivery of better care. 
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                                                         AIMS OF THE STUDY 
 
1. To study the socio-demographic and the clinical profile of  patients with leprosy, 
accessing a tertiary care centre and to assess their disability status. 
2. To study the health care utilization pattern and its consequences. 
3. To assess the following parameters: 
(a) the level of activity limitation and safety awareness using the SALSA scale. 
(b) the level of participation restriction using the P scale. 
            (c) the mental health status of patients with leprosy using the GHQ 12         
               and the ICD 10 primary care criteria for depression.  
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                                               LITERATURE REVIEW 
 
Introduction: 
                       Leprosy is a chronic infectious disease caused by Mycobacterium leprae; it usually 
affects the skin and the peripheral nerves, but has a wide range of clinical manifestations. M. 
leprae is spread from person to person, primarily as a droplet nasal infection. The incubation 
period is generally 5 – 7 years, the peak age at onset is young adulthood, usually 20 –30 years.1 
 
History of leprosy: 
                       The first recognizable report of leprosy was written in the middle of the second 
century, AD.18  Though the bacterium was discovered in 1873, potentially effective therapies 
came into being only in the 1920s. Dapsone was introduced in 1949, and the multi drug therapy 
as in current usage came into being in 1982.19 While humans are considered to be the major host 
and reservoir of M. leprae, other animal sources, like the armadillo have been incriminated as 
reservoirs of infection. There is no evidence to suggest an association between leprosy and HIV 
infection. BCG vaccination is known to have some protective value against leprosy.1 
 
                       Leprosy has been described as a  disease that destroys not only the body but the 
soul: it is a disease that slowly turns a person into a thing.20  The disease and its associated 
deformities are responsible for social stigma and discrimination against the patient and their 
families in many societies.1  
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                   Figure 1: Prevalence of leprosy in India. 
 
The Prevalence Rate 1.06 per ten thousand population 
MB Proportion 45.83% of new case detected 
Female Proportion 32.67% of new case detected 
Child Proportion 10.19% of new cases detected 
Visible (Grade II) Deformity proportion 1.69% of new cases detected 
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Epidemiology and current statistics: 
                        As on the first of April 2005, the South-East Asia Region (SEAR) is the only 
region where the leprosy prevalence is above the elimination goal of one case per 10,000.  
 Leprosy in the SEAR countries contributes to 69% of the global prevalence and 81% of the total 
newly detected cases. In the region, three countries were still having a prevalence rate (PR) 
above the elimination goal: India (PR: 1.34), Nepal (PR: 1.9), and Timor Leste (PR: 4.7).  India 
alone represents 80% of prevalence and 88% of new detected cases in the SEAR.5 With India 
achieving elimination in December 200512, the SEAR is also expected to achieve elimination.3 
The NCDR as of April 2005 was 2.34.4 The national statistics as of November 2005 are  shown 
in Fig. 1.  The prevalence rate is 1.06/10,000, 45.83% of the newly detected cases are 
multibacillary and children constitute 10.19% of new cases. Women form 32.67% of all cases. 
The proportion of patients with grade 2 disability is 1.69 % of new cases detected.5   
 
Importance of the NCDR : 
                        Trends of a disease are observed in order to look for change and explore  the 
reasons for such change.  Two indicators used to monitor such trends in leprosy would be the 
prevalence rate and the NCDR. The NCDR is a proxy indicator for the incidence of the 
disease.6,8,9,21 The WHO has proclaimed that leprosy is no longer a public health problem at the 
global level.2,22 Though the prevalence levels and hence the case loads have fallen remarkably,1  
the case detection rates  have continued to be more or less  the same or are even increasing.2,22-29 
Meima et al, 24  examined the  global trends in NCDR from 1985 to 2000 and found no decline in 
case detection. Interestingly though, the recent national data show a significant fall after 2003- 
2004.4,5 This seems to be  true across the country4-11 with the exception of  Bihar, where 
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Vijayakumaran et al30  reported no change in NCDR. It remains to be seen whether this trend 
will be sustained.21 
 
                        Many researchers have attributed the fall in prevalence to operational factors and 
policy definitions rather than to any breakthrough achievement in control of transmission .27  In a  
study from Chattisgarh, Pandey et al31 showed that not only had the NCDR remained static, but 
that a higher proportion of newly diagnosed cases were likely to be in the MB spectrum, with 
attendant higher risk of transmission. Also, there was a higher proportion of patients with grade 2 
deformity.31 Similar results were seen in recent studies evaluating the proportion of MB cases 
among newly detected cases from TamilNadu,6,10 Andhra Pradesh8 and Orissa.7 This is 
suggestive of both ongoing transmission and delayed presentation.31 
 
      Integration: 
                        Integration means active involvement of the general health services in leprosy 
control activities. The rationale behind this is that the general health services are widely 
distributed and have close and frequent contact with the local community, and involving them in 
leprosy control will improve case finding, case- holding and the awareness of the local 
community about the disease. In short, integration will improve efficiency and effectiveness, 
optimize the use of resources, promote greater equity, reduce stigma and discrimination and 
ensure long- term sustainability.1,2  
 
                        In practice, however,  Kalk et al32  found that  decentralization seemed to have 
contradictory results; while leprosy control in Brazil took advantage of the decentralization 
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process; in Colombia, it almost collapsed.  There were difficulties in transit towards integration, 
especially when essential requirements were not in place.33 It has been found that in chronic 
diseases like leprosy and tuberculosis, adherence to therapy is poor.2,34 While MDT coverage is 
increasing, decentralization in the forms of accompanied MDT, though operationally simple, 
may prove detrimental to the patient in the long run.34 If programmes are allowed to slacken 
prematurely, there may be a resurgence of disease.35 In an analysis from Sri Lanka looking at the 
case detection profile after integration of leprosy care into general health services, it was found 
that minor public facilities were being bypassed , although, ideally, they should have been the 
starting point of health care.36 Though integration into primary heath care is beneficial and has 
been completed in India,13 leprosy surveillance and post elimination strategies should be in 
place, so that the individual leprosy patient is not sacrificed for the benefit of the many.37  
 
Utilization profile: 
                        Though the biological disease with its symptoms is the same everywhere, the 
social meaning is very different  and this affects people's coping strategies in dealing with their 
disease and treatment and  consequently their help seeking and adherence behavior.38-40 Since 
leprosy results in a great variety of symptoms and carries an implicit threat of stigmatization, 
especially for women, it also results in great variety of routes by which patients bypass preferred 
or alternative sources of help before they commit themselves to the health services, receive a 
correct diagnosis and start treatment. This is compounded by lack of knowledge regarding the 
disease.41 
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Delays in presentation and treatment: 
                        The WHO recognizes the importance of early detection and effective treatment as 
the keys to breaking the chain of  transmission and eliminating leprosy.41,42    Delay in diagnosis 
and start of treatment is defined as the time taken from first being aware of the symptoms of the 
disease through to the  start of effective treatment.26,41  It can be divided into physician or health 
care system related and patient related. It is good neither for the patient because of the risk of 
adverse consequences, nor for the community because of the risk of prolonged 
transmission.22,43,44 Available data suggests that  the delay should not be longer than 6 months.26, 
43 In a study from Brazil, it was found that  71% had a delay of 7 months or more and it was 
significantly associated with nerve function impairment.45 It has been found that under-diagnosis 
is more common among the borderline lepromatous or lepromatous group.22 
 
                       The delays have been as long as 15 years in various studies.26,44,46-50  Deps et al26 
discussed the  delays between endemic and non endemic countries. They compared the delay  in 
non endemic countries { Kuwait(10.5 months), Cuba (16.6 and 10.7 months, from 2 centres 
respectively), Paraguay(47 months), China(39 months), Ethiopia  (28.8 months among males and 
27.6 months among females) } against those in endemic countries { Brazil ( 71.1 % more than 6 
months), India ( 82.3% > 1 year)51, Nepal(37.6months)}. In their study, the mean delay in 
months was longer in multibacillary (27.2 + 39.8) patients than in paucibacillary (21.3 + 44.3) 
patients.  The average delay in their study was 25.25(+ 41.4) , with a median of 12 months and a 
range of 0 – 36026.  Kumar et al52 reported a mean delay of  65 months in  MB  cases as 
compared to 29.2 months in PB cases,  among patients from the rural areas of Agra district. A 
study from Nigeria found that the patient delay was 4.5 months and the health system delay was 
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10 months.53 This draws attention to the need for better and specific training, especially in the 
context of integration.2,53 Delay in referral was a very existent problem, with a range of 1- 12 
months and this depends upon the knowledge and skills of the physician  in the early diagnosis 
of leprosy. 54 
 
Factors associated with risk of delay: 
                       The best way to prevent impairments is with early case detection,  implying lesser 
delays.38,43,44,54-56 In a study by P.G. Nicholls et al,41 from West Bengal and Bangladesh,  
repeated contacts with health services contributed to delay. They identified those at risk as 
individuals aged over 35 years and those continuing to rely on traditional or alternative 
treatments. Men aged 35 years and above had a mean delay of  24.2 months, while those aged 
below 35 years had a  mean delay of 18.8 months in Bangladesh, while the corresponding figures 
from Purulia were 18 and 15 months respectively. The corresponding values for women were  
35.5 and 16.1 from Bangladesh and 23 and 25 from Purulia respectively.41 Women had a longer 
delay(63.8 months) as compared to men(41.2 months) in a study from Maharashtra.48 
 
                        In a study by Nicholls PG et al,43 delay was found to be associated with older age 
groups, MB disease and with grade 2 disability. Longer delays were noted in the pure neural 
type. Signs of reactions were triggers for early presentation. The authors opine that an agreed 
threshold, defining early presentation, may serve as an indicator of good practice. Affected 
individuals need time to be aware of the significance of their signs and symptoms and to 
eliminate the possibility of a simple skin disease. The study suggests a period of no more than 6 
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months between onset of symptom to diagnosis.43  Illiteracy was associated with delay49 and 
patients with better literacy tended  to seek consultation early.46 
 
                        In a study by Kumar and Anbalagan,46 from Chingleput in 1980-81, it was found 
that  73.33% of the study population tended to change their medical agencies , an  average of 2.6 
times. This tendency to change was found to be related to the severity and duration of disease, 
and to the male sex.46  In a study from Nigeria, patients  paid an average of 2.7 visits to the 
doctor before leprosy was diagnosed.53 
 
Role of awareness in determining the utilization profile: 
                        Ignorance, lack of awareness and stigmatization in the general population prevent 
people from taking help-seeking actions, and those with leprosy make many visits to the general 
health care providers/ dermatological services before the final diagnosis of leprosy is made, 
especially in low endemic areas. Patients report dissatisfaction with treatment due to inadequate 
knowledge about the diagnosis, chronicity of the illness and the permanent nature of the sensory 
impairment. This lack of awareness would prompt them to seek multiple and not always 
effective  treatment options, thereby compounding both the physical and the psychological 
impairment of what is a chronic disease, especially when care after cure is also considered. This 
situation could be easily averted if effective measures for educating the patient are put in place, 
thereby saving manpower and money, both to the patient and the provider.57,58 A study from 
Bangladesh in 1999 showed that knowledge about leprosy was significantly less than that about 
tuberculosis. 62% replied that they did not know about leprosy while 92% were able to mention 
a symptom of tuberculosis, though both diseases were equally rampant in the locality.59  
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Education and improving awareness levels can go a long way toward improving adherence and 
prevention of disability.38,40,58,60,61 
 
Importance of following up patients with impairments, active or treated: 
                        The utilization pattern of leprosy patients needs to improve with regard to the 
disease and the primary and the secondary impairments, preferably at the first point of contact 
with the health services, because a delayed detection rate will only lead to increased deformities. 
Though the number of cases on the rolls may have come down with the introduction of MDT and 
now, fixed duration(FD) MDT, the work load may not decrease because many patients will need 
continued care, support and counselling.62,63 Croft et al64 found that patients with PB leprosy and 
no nerve function loss had a 1.3% risk of developing nerve function impairment(NFI) within 2 
years of registration. Patients with PB leprosy with nerve function loss or MB leprosy without 
nerve function loss had a 16% risk. Patients with MB leprosy and nerve function loss at 
presentation had a 65% chance of developing new NFI within 2 years of registration. These 
groups were classified as low, intermediate and high risk, depending upon the possibility of 
developing a NFI. They suggested  that follow up of patients after release from treatment be 
done as follows: patients in the low risk group need no follow up beyond the course of their 
chemotherapy, intermediate risk patients need to be followed up for 1 year, and the high risk 
group should have at least 2 years of surveillance for new NFI.64 
 
Contacts: 
                        Surveillance measures including contact tracing are also important,2 considering 
that residential transmission is the strongest known risk factor for leprosy.25,65-67 This could 
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improve the utilization profile of the cases detected from among contacts who constitute a 
significantly large group, considering that the proportion of patients who have known leprosy 
contacts may be as high as 45%.68 
 
Impact of leprosy on the economic status of the patient: 
                        The current leprosy elimination strategies focus almost exclusively on delivery of 
leprosy diagnostic services and MDT; however, the specific problems of people newly diagnosed 
with leprosy or cured with MDT primarily relate to nerve function impairment  and to the social 
and the economic consequences of the diagnosis of leprosy.69 Leprosy related impairments and 
stigma may rapidly lead to unemployment, community dislocation and destitution. The percent 
of dehabilitation is equal to the degree of disability and intensity of social stigma.70-72 
 
 
Loss of income and other indirect economic losses: 
                       In a study from Nigeria, 43 out of 129 patients lost one half to two thirds of their 
income due to leprosy.49  Raghavia et al73 stated that 72 % in their study group experienced wage 
loss and that 7 % had to quit or change their job owing to leprosy. Arole et al74 found that 16 – 
44% of patients reported a fall in their income. Kumar and Anbalagan75  noted that the 
occupational status of  46.22 % of patients were adversely affected due to leprosy and 51% 
showed a reduction in their monthly incomes. A study by Kaur et al72 found that 85 % of 
economically productive individuals had to turn to beggary owing to leprosy. In a study done by 
Kumar and Anbalagan in 1981,46 it was found that 6.66% of patients had to sell their property or 
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take a loan to meet the medical expenses. 45.78% of patients spent between Rs.100 to Rs.10000 
for their treatment.  
 
Employment issues: 
                        When employers were questioned about their reservations regarding appointing 
leprosy patients, the prime reason for a negative attitude towards employing leprosy patients was 
functional- that "the candidate would be unable to do the job".76 
 
                        In a study by Withington et al,69 it was found that the following factors were 
found to be associated with nerve function impairment: manual occupations, status as beggar or 
day labourer, presence of dependants, MB disease and paradoxically, higher income groups.  
 
Cost measurement: 
                        Direct costs are costs of resource usage related to the condition being studied, 
including medical and non medical costs. Medical costs include doctor fees, medication costs 
and investigation charges. Non medical costs refer to costs spent on having to hire a helper, 
family care giving, cost of transport, stay and food for the patient and helper. Indirect costs 
include productivity losses due to the condition resulting from premature death or loss of income 
because of loss of job, sick leave, etc. The sum of all the above would indicate the economic 
burden.77 
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Costs of MDT: 
                       The cost of MDT in 1985 was pegged at US $6.00 per paucibacillary patient and 
the cost of  MBMDT at US $26.00 per year. 63  Revankar in 1986 calculated the cost of MDT . 
WHO MB (adult) was found to cost Rs.359.00 and WHO MB (child) Rs.179.50 per year. For PB 
MDT, the costs were Rs.28 for an adult and Rs.14 for PB (Child) per patient. This study 
compared the then existing regimes of antileprosy drugs: Isoprodian-R(German Leprosy relief 
association), Isoprodian – Rifampicin(Borstel), WHO- ILEP, and IAL(Indian association of 
Leprologists) and found the WHO ILEP regimen most cost effective.78 The costs due to drugs 
alone would account for  10 – 20 % of the overall expenditure of a leprosy control programme.78  
 
Need for socioeconomic rehabilitation: 
                        Provision of socio economic rehabilitation assistance is not inexpensive. Adding a 
socio economic dimension to leprosy services may undermine already stretched diagnostic and 
treatment services, whose staff, generally do not have the training, time or resources to consider 
such issues. However, if neglected, these issues can potentially increase costs in the long run. 
Potential benefits  will include decreasing rates of re admission to hospital, decrease in 
disabilities, and the wider benefits of socio economic development for this very vulnerable 
group.69 
 
Disability grading: 
                        Leprosy should be regarded as a problem unsolved so long as patients continue to 
present with disabilities,35 which indicate delay.79,80 The national disability rate is low at a grade 
2 disability rate of  1.69% of all newly diagnosed cases as of November 2005.5 A decade ago, 
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this rate was 5.96% for India,  6.4% for the SEAR, and 7.3% globally.79 Early detection of nerve 
function impairment is vital for prevention of disability.43,44,54,55,64  
 
WHO disability grading: 
                        The WHO has advocated a disability grading for use in leprosy since 1960 with 
one of the aims being to assess the disability burden attributable to leprosy in the community so 
as to plan necessary action. Suggestions for proper usage of this grading system have been put 
forth.79,81 In the International Classification of  Impairments, Disability and Handicap, 
impairments are defined as problems in body function or structure such as significant deviation 
or loss.81,82  A deformity is a structural, usually visible, impairment. A defect could be either a 
structural or functional impairment.  Disability is defined as any restriction or lack of ability to 
perform an activity in the manner considered normal.79-81 Although from the current definitions, 
it is evident that the WHO disability grading system grades impairments rather than the overall 
disability status of a   patient,81,83 its strength  lies in its widespread use and hence 
comparability.84   
 
Prognostic factors for nerve function impairment: 
                        The presence of impairment at diagnosis is considered to be a major risk factor  
for subsequently developing new impairments, in both PB and MB patients.55, 85 MB  patients are 
at highest risk of developing reactions and NFI.55 De Oliviera et al55  from Brazil report grade 1 
or 2 impairments in 12% of PB and 37% of MB patients. Percentages of impairment (WHO 
grades 1 and 2  together)  at first examination vary greatly worldwide. Impairment figures for PB 
patients range from 10 – 55 % and for MB patients from  31 – 56 % depending upon the study 
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population and the national prevalences.55,80,86 In  a recent study at a tertiary care hospital , the 
JALMA, Agra, the disability rate was 40% and this included grade1(18%) and grade 2(22%).52 
Pimentel et al45 from Brazil found a similar proportion of grade 2 disabilities, though 33.67% 
had a grade 1 disability. In this study, based in a tertiary care centre, multibacillary patients were 
followed up for a mean period of 65 months for nerve function impairment, and it was found that 
the grade 2 impairments, had decreased to 20.39% at the end of follow up. The occurrence of 
overt neuritis was seen in 34% of patients during treatment and 45% during follow up with 
relative risk for developing NFI of 1.76 and 1.80 respectively.45 Males have been found to have 
higher deformity rates compared to females(8.9% in males and 2% in females) in a study from 
JALMA.52 
 
Disability assessment, activity limitation and its impact on the patient: 
                       Disability assessment is very important not only to evaluate the effectiveness of 
the control programme but  also for the patient , whose most important worry is the stigmatizing 
deformities that leprosy patients suffer.80 Information on the impairment and activity status of 
people affected by leprosy may be used for: (i) decision making and management concerning 
(physical) rehabilitation of individual patients, (ii) assessing the effectiveness of a leprosy 
programme in preventing the development of (further) impairments and activity limitations, and 
treatment of pre-existing ones, and  (iii) planning of resources needed for treatment and care of 
patients with impairments and activity limitations, before and after release from drug therapy.87 
Disability  due to leprosy must be treated as part of a total disability rehabilitation program.70 
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                        Chen Shumin et al88 assessed problems in self care, daily activity, productive 
activity and social participation. The patients were asked one question on each of the above 
domains with 3 possible responses corresponding to the level of difficulty. 3.2% had great 
difficulty in self care, and 5. 6% in daily activities. However, 22.7% had some problems in self 
care while 28.3% had some problems in daily activity. The rest had no problems. 88  
 
SALSA:14  
                        The SALSA was developed between 2000 and 2002  as a standardized tool to 
measure the activity limitation and the safety awareness encountered by people affected by 
leprosy, diabetes and peripheral neuropathy in both  low income and  developed areas. This 
instrument has been developed by experts in the field with special emphasis on cohorts of 
leprosy patients.  
 
                        It can be administered in less than 10 minutes and can provide a standardized 
measure of activity limitation. It examines activity limitation directly- what respondents consider 
they can or cannot do, or can do with difficulty. It also indicates the degree of restriction of 
activities because of their awareness of risk of injury. Thus, it can be a tool for the health 
workers to make sure that the level of avoidance behavior exhibited by the patient is appropriate.  
 
                        The SALSA  has a total of 20 questions, 5 on mobility , 3 on self-care, 7 on work 
involving the hands , and 5 on dexterity of the hands.  A low score indicates little difficulty with 
activities of daily life while a higher score indicates more difficulty with daily activities.  In the 
development of this scale, based on data from 568 cases, Velema et al,14 found that the score 
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varied from 10 – 75 with a mean of 32 and a median of 27. There was an increase with age. The 
safety awareness score is calculated by counting all the 4s which are circled, as instructed in the 
user manual. The association of the SALSA score with the EHF impairment score was strong. 
Mean SALSA scores increased from 23 in the group without impairments to 44 in the group with 
the highest impairment scores. 
 
                        The  SALSA  user manual recommends its  use in combination with  impairment 
and participation restriction assessments . 
 
Handicap or participation limitation: 
                       Participation is the nature and extent of a person’s involvement in life situations in 
relation to impairments, activities, health conditions and contextual factors, e.g., participation in 
community activities. Restriction in participation can be referred to as handicap.20 Leprosy is 
associated with significant stigma,28,71,72 probably second only to AIDS.89 The greater the 
disability, greater is the level of stigma.89 Stigma against leprosy affects all aspects of leprosy 
control. Some patients would rather conceal their illness than suffer the social rejection, which 
may accompany revelation of the diagnosis. In addition for fear of being stigmatized, some 
patients may discontinue chemotherapy prematurely. Patients report late for treatment owing to 
stigma, thereby leading to an increased transmission of infection in the community. Finally 
patients who report late may suffer deformities and disabilities, which could have been prevented 
if they had reported earlier.20  
  
 24
 In some cases a mere diagnosis  of leprosy is sufficient handicap for the affected 
person, even when there is no disability.20 The initial despair may lead to depression in some and 
aggression in the others.90 It is the perceptions that people have about leprosy rather than the 
disease itself that significantly influences their attitude towards leprosy and leprosy 
patients.20,49,71,72,91 Several studies have shown that patient awareness regarding leprosy is low, 
both in India and globally.49,57,59,92-94 This low level of awareness in patients leads to unnecessary 
restrictions.95  However, Pal and Girdhar present conflicting evidence, based on their study of 
307 patients from among the out patients attending JALMA, Agra.96 A study from Delhi placed 
awareness at only 60 % in 2003, more than a decade after the arrival of MDT.91 However, 
another study done in 2003 was encouraging in that it showed a high level of acceptance of 
patients by their families; in fact patients felt that the community was not concerned as long as 
there was no ulcer or deformity due to leprosy.97 A study by Tsutsumi et al,98 opined that though 
society might appear to have come to accept leprosy patients, this acceptance was only 
superficial and patients still suffered from feelings of isolation.  
 
                        In a study by Kopparty, 57 % of patients experienced their deformity as a 
handicap which caused social and  economical problems while the rest did not. 82% of families 
accepted deformed patients who did not have any handicap. However, if patients were both 
deformed and handicapped only 64% of families accepted them. 99  
 
The Participation Scale ( P scale): 
                        This is the outcome of an international research project to develop an interview-
based scale that would address all the dimensions of participation. This is based on the fact that 
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better  results are likely to be achieved  in rehabilitation programmes if special attention is given 
to clients’ opinions and ideas, which are rarely included in the feedback.100,101 
  
 The P scale has been used in  one study concerned with evaluating the 
effectiveness of  intervention programmes to reduce participation limitation.17   
 
Risk factors for participation limitation: 
                        In a  multi-centre study by PG Nicholls et al,102 risk factors for increased 
participation restriction included being hospitalized at diagnosis, stress at diagnosis, needing to 
practice self care at home, fearing abandonment, knowing that leprosy may be transmitted to 
others and suffering from another disease, while having family members previously affected by 
leprosy and knowing that leprosy is curable led to decreased participation restriction. Education 
was an important issue with individuals without any education experiencing more participation 
restriction than those with 6 or more years of education.102 
 
Gender differences in participation and stigma: 
                       Women tended to hide the disease more often than men, because of the fear of 
social stigma or dehabilitation.48,89,103 They faced definite social and psychological problems 
despite their socioeconomic status. They were isolated more often from all activities than men. 
30 % of women reported constraints on social outings with the family and travel. Attending 
celebrations in the neighbourhood was prohibited for men(10%)   but more so for 
women(17.9%).48 Also in certain settings, the lack of privacy was deterrent to proper 
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treatment.95,104 Most of the health care workers being men , they considered the women inferior, 
in line with existent social norms.95 
 
Role of health care variables:  
                        Side effects of anti leprosy medication were perceived as triggers to exposure and 
increased people’s fear of stigmatisation,  along with the fear of exposure. Visible symptoms, 
monthly visits to the health post, blister-pack with the medicines, and for some, their skin turning 
black due to clofazimine were all occurrences that they wanted to hide and were seen as triggers 
that could lead to exposure and thus endanger their social position within the family and the 
community.38 The attitude of the health care workers was an important issue.95,104 Jopling 
stresses that availability of MDT is the key to reduction of stigma.90 Brandsma et al105 claim that 
widespread use of MDT along with improved leprosy control measures have led to decrease in 
stigma and to the number of people presenting with grade 2 disabilities.  
 
                        Interviews on awareness of their disease and its symptoms, can serve as a means 
of action in themselves and hence are to be considered a step in the right direction. Patients, 
given the opportunity to express their opinions, gain a sense of awareness that they have the 
ability or power to improve their status.101 
 
Mental  health status in leprosy: 
                       Though much has been studied about the medical nature of the disease, the 
psychosocial aspects of leprosy remain largely unexplored.106 A drawback of the WHO model is 
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that it categorizes personality disorders as impairment due to leprosy. This creates the impression 
that leprosy affects one’s mental function, a fact that is not supported by scientific evidence.20 
                        Impairments are interpreted as negative perceptions by the patient. As a result, the 
patients develops negative expectations of himself with respect to life.89, 106 This is likely to 
create a variety of emotions including anxiety, fear and          depression.57,107-109 Depression was 
the most common followed by anxiety neurosis.107 Denial of the disease is related to feelings of 
insecurity and can thus be a strong contributing factor to non adherence of treatment.38 
Eventually, the patient loses self esteem and may beome withdrawn or adopt negative 
behavior.20,80 A variety of emotions are intensely experienced by patients with grief at the 
diagnosis appearing to be the strongest and the most general reaction.106 The diagnosis of leprosy 
came as a severe shock to the patients.101 
 
                        As early as 1980, a study from this center found that the prevalence rate of 
psychiatric disturbance among leprosy patients was 99 per 1000, which was significantly higher 
than the prevalence in the general population.110  Prevalence of mental distress  over the previous 
one month was studied  by Leekassa et al.111 This study from Ethiopia found that mental distress 
was higher in patients with leprosy as compared to those without leprosy with an odds ratio of 
7.14. Among leprosy patients, 18.5% had suicidal ideation over the previous 1 month as 
compared to 6.3% of non leprosy patients.111  The psychiatric morbidity was shown to increase 
with increasing disability grades in a study from Bangladesh.98 
 
                        Patients with deformities had a higher level of psychiatric        morbidity.98,109-112 
Mental distress was seen in 37.5% of patients with no disability, 43.4% with EHF score of 1-4, 
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and 65% with a higher EHF score in a study from Ethiopia.111 Psychiatric disturbances were seen 
in 63.3% of deformed patients as compared to 36.7% of non deformed patients, in a study from 
Tamil Nadu.110 
 
                        Studies confirm that corrective surgical procedures decrease psychiatric morbidity 
and recommend corrective surgery as part of rehabilitation.108,112 Also it was found that patients  
with increased emotional lability were more likely to default on treatment and in the days of 
dapsone monotherapy, this was presumed to be one of the causes for the development of dapsone 
resistance.113 It has been suggested that it is not only the patient, but also the family that needs 
psychological help. Mass education and psychiatric counseling should be offered in needy 
cases.57 
 
The GHQ 12 [General Health Questionnaire 12] ( Goldberg 1972): 
                        This is an instrument of known reliability used to screen for psychiatric morbidity 
in general practice. The suggested threshold score (mode) is 2/3 which has a median sensitivity 
of 83.7% and a specificity of 79.0%.114  A previous study in a  clinic based setting in Bangalore 
found that psychiatric morbidity was positively correlated to physical disability (p < 0.05), 
knowledge about the disease (p < 0.01) and social, emotional and health maladjustment (p < 
0.01), but not with duration of illness (p >0.05). The mean GHQ score in this study was 5.43 (+ 
0.68).115 Another study by the same authors found that the psychological morbidity was lower in 
patients with leprosy when compared to those with psoriasis. Endogenous depression was 
diagnosed in 96.6% of patients with psoriasis and 93.3% of patients with leprosy using the GHQ 
12. Memory and concentration lapses(60%), paranoia(20%), hallucinations(6.6%), sleep and 
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appetite loss(76.6%) were more in patients with leprosy , while somatic symptoms, suicidal ideas 
and attempts were more in psoriasis. 96.7% of leprosy and 100 % of psoriasis  patients had  
depression. However, once psychiatrically morbid, patients with leprosy were more significantly 
ill than those with psoriasis.109 John et al114 used the ICD 10 criteria for validation of the Tamil 
version of the GHQ 12, and found that at a cut off of 2/3 the sensitivity was 97.0% and a 
specificity of 55.7%.  
  
                       Psychiatric co-morbidity was found to be very common among displaced leprosy 
patients who faced rejection by their  family and the community.107 The provision of appropriate 
mental care and a programme to decrease discriminative actions against leprosy patients are 
essential to improve their mental status.98 
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                                             MATERIALS AND METHODS 
 
Setting :  
                         Department of Dermatology, Venereology and Leprosy, Christian Medical 
College, Vellore. 
 
Study design:                        
                        Cross sectional descriptive study. 
 
Duration of study: 
                         January 2005 to June 2006. 
 
Study population:          
                       All patients with leprosy accessing the out patient clinic, Department of 
Dermatology, Venereology and Leprosy, Christian Medical College, were eligible for inclusion 
in the study.   
 
Inclusion criteria: 
♦ All newly registered patients diagnosed to have leprosy, seen during            the 
study period at the out patient clinic, Department of Dermatology, Venereology 
and Leprosy, Christian Medical College, Vellore. 
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Exclusion criteria: 
♦ Patients who had been diagnosed and / or treated at Christian Medical     
College, earlier. 
♦ Those unwilling to participate in the study. 
 
            The proforma included information on the demographic details of the patient, the 
diagnosis and the clinical features, past history, history of contact with leprosy and disability 
status.(Annexure 1A) The number of patches and nerves were considered, and the patient 
classified as multibacillary(MB) or paucibacillary(PB) as per NLEP guidelines.116 Though the 
diagnosis of leprosy and classification into active and treated cases were primarily clinical, all 
patients had their skin smears tested.  In doubtful cases a skin or nerve biopsy was done to 
classify the disease. 
  
 WHO disability grading :81, 117 
The WHO grading was done as follows: 
GRADE                                DEGREE OF IMPAIRMENT 
Hands and feet 
0 No anesthesia, no visible deformity or change. 
1 Anesthesia present but no visible deformity or change. 
2 Visible deformity or damage present. 
 
Eyes  
0 No eye problems due to leprosy, no evidence of visual loss. 
 32
1 Eye problems due to leprosy present but vision not severely affected. 
2 Severe visual impairment, vision <6 /60, not able to count fingers at 6 m. 
 
  The WHO disability grade was the highest grade seen in either eye, hand or feet 
assessment. The minimum score was 0 and the maximum, 2. Semmes-Weinstein filaments were 
used for detecting sensory loss over the palms and the soles and voluntary muscle testing was 
done using the Medical Research Council(MRC) scale as per recommended guidelines.81, 118 
 
Informed consent was obtained from the patients (or their guardians in the case of 
patients aged 15 years or less) before assessment of the parameters detailed below.(Annexure 2) 
Patients aged 15 years or less, were excluded from assessment of activity and participation 
limitation and mental health status. Newly diagnosed patients were also excluded from the above 
assessments unless they were able to return after a period of 4 weeks from the time of diagnosis, 
for administration of the scales. Patients who were not conversant in at least one of the following 
languages, namely English, Tamil, Hindi or Bengali were not administered the above scales. 
 
Utilization profile: 
Patients were questioned about their symptoms, contacts with the health care, 
costs incurred, presence of visible deformity at the time of presentation, occurrence of deformity 
during or after treatment, history of reactions and knowledge about their diagnosis.        
(Annexure 1B). Patients aged less than 15 years were not assessed regarding the knowledge of 
their diagnosis. The interval between the first onset of symptoms to the time of presentation was 
noted as patient related delay.  Delays between presentation and diagnosis and between diagnosis 
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and treatment, were taken to account for physician or health care system based delay. The overall 
delay was the sum of the above two components. These details were traced as accurately as 
possible, subject to patient’s recall as follows. The contacts with the health care system were 
noted and the total number of physician patient contacts summed up. Any instance of seeking 
alternative medicine was also recorded. In patients who have been released from treatment(RFT), 
details of self medication, and any symptoms post RFT  were recorded in the proforma. 
 
Economic Burden: 
The costs of medical care were traced and the cost incurred over the previous year 
was noted (to minimize recall bias).  
      Total cost = direct medical + direct non-medical + indirect cost. 
      Non medical costs = money spent in having to hire a helper, family care giving, cost of  
      transport, stay, food for patient and helper. 
      Direct medical costs = doctor fees, medication costs, investigation and procedure charges                                      
      Indirect costs = losses due to sick leave, change or loss of job.77 
      Details concerning the patient’s income, occupation and the type of housing were entered  
      in the proforma.  
 
P scale:15, 17 
                       The P scale was also administered by the principal investigator in the out patient 
clinic in the patient's vernacular. The scores are interpreted as follows : 
         0 – 12 : No significant restriction  
       13 – 22 : Mild restriction 
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       23 – 32 : Moderate restriction 
       33 – 52 : Severe restriction 
       53 – 90 : Extreme restriction 
 (Annexure 3) 
 
SALSA:14 
                       The SALSA was administered by the principal investigator  in the out patient 
clinic in the language they were most familiar with, and responses were marked in the SALSA 
scoring sheet and the total score summed up. The circled 4s were added up to give the safety 
awareness score(Annexure 4). 
 
Mental health impairment: 
                        The  GHQ 12107, 109, 115  was used for screening for depression and the  ICD 10 
criteria were then applied to confirm a diagnosis of  depression.  These were administered on 
different days to avoid patient fatigue and repetition of similar questions. In patients who were 
unable to return for administration of the second scale, the details of the second scale was 
unavailable for analysis. The 4 responses of the GHQ 12 were marked as follows:0,0,1,1 
respectively. For the ICD 10 criteria , both mandatory and at least 2 of the additional criteria 
were required to be met  to diagnose a case of depression.119 (Annexure 5 & 6). 
 
Translations of the P scale, the SALSA and the GHQ 12: 
 The SALSA was translated into Tamil and Bengali, the P scale into Hindi and 
Bengali and the GHQ 12 into Hindi and Bengali. The translations were done as follows:  the 
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translation into the vernacular and the back translation was done by medical professionals 
familiar with the concepts considered in the scales, viz participation , disability, mental health 
status etc, and fluent in the languages into which the scales needed to be translated. A discussion 
between the translators and the back translators was held to ensure that the translation is 
satisfactory and to resolve differences to arrive at a final translation.  The Tamil version of the 
GHQ 12 was obtained from Mental Health Centre, Christian  Medical College, Vellore, and the 
Tamil version of the P scale from Scheiffelin Leprosy Research and Training Centre, Karigiri, 
Tamil Nadu. The Hindi version of the SALSA scale was obtained with permission from the 
SALSA Collaborative group through Dr.  Johann Velema. 
 
 
Sample size : 
  All the patients who sought care at Christian Medical College for leprosy for the 
first time, during the study period, were eligible for inclusion in the study. Consecutive patients 
who fulfilled the relevant inclusion criteria were included. Patients who gave informed consent 
to participate in the interview were chosen and the scales administered to them over 2 days to 
avoid patient fatigue. Patients who could not stay back for the interviews due to time constraints, 
were lost to inclusion. 
 
Statistical methods: 
 All the data were entered in and analysed using SPSS 13 software. Categorical 
variables were analysed using Chi square test. Relationships between variables were assessed 
using the Pearson's product moment correlation and Spearman's rho. Comparisons of continuous 
variables between categorical levels was done using independent sample t test and analysis of 
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variance, though Mann- Whitney test and Kruskal- Wallis tests were used when the required 
assumptions were not met. 
 
Institutional Research Committee approval: 
 The study was approved by the Institutional Research Committee, Christian 
Medical College. 
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                                                                    RESULTS 
 
PROFILE OF THE CLINIC ATTENDEES: 
                        The total number of all new patients registered at the Department of Dermatology, 
during the year 2005 was 7927, with 4773 males and 3154 females. The total number of patients 
with leprosy seen in Dermatology OPD during the study period was 198.  
 
Socio demographic profile:  
Age and sex distribution: 
 Of these 198 patients, there were 162 (81.8%) males and 36 (18.2%) females. The 
youngest patient was 3 years old and the oldest 83, with a median age of 35 years. The   mean age 
was 37.03 (± 14.353). The age and sex distribution of patients are shown in Fig. 2. 
 
Distribution of patients according to state: 
 The maximum representation was from West Bengal (47.98%), followed by Tamil 
Nadu (18.18%), Jharkhand (14.65%) and Andhra Pradesh (6.06%) in that order, with smaller 
contributions from Assam, Bihar, Meghalaya, Uttar Pradesh, Madhya Pradesh and Karnataka. The 
statewise distribution is shown in Fig. 3. 
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Figure 2:  Age and sex distribution of the clinic attendees. 
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Figure 3: Distribution of the clinic attendees according to state. 
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Disease characteristics: 
Duration since onset of illness: 
                             The mean duration since onset of disease was 74.35 (± 97.257) months, with a 
median of 36 months,  maximum of 624 months and a minimum of 0.  However, this maximum 
number represented a newly diagnosed patient who presented with an unrelated dermatological 
complaint, and excluding him, the range was 480 months and the mean duration was 71.50 (± 
89.031) months. 
 
Disease spectrum, diagnosis and presenting symptom: 
                       Of the 198 patients, 115(58.1%) patients had active disease and 83(41.9%) were 
inactive.  67.7 % were in the MB spectrum and 32.3% in the PB spectrum. A diagnosis of leprosy 
was first made in our centre in 35(17.7%) patients. The diagnoses in these patients are shown in 
table 1.  25(71.4%) of the newly diagnosed patients belonged to the MB spectrum. The state-wise 
distribution of these patients is shown in Fig. 4. 
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Table 1: Diagnoses of the clinic attendees. 
Diagnosis  All patients n(%) Newly diagnosed cases n(%) 
Treated, could not be classified   36(18.2)   0 
Tuberculoid   13(6.6)   0 
Borderline tuberculoid   68(34.3) 16(45.7) 
Borderline      5(2.5)   0 
Borderline lepromatous   25(12.6)   3(8.6) 
Lepromatous    34(17.2) 13(37.1) 
Pure neuritic   17(8.6)   3(8.6) 
Total  198(100) 35(100) 
 
 
 
Figure 4: Distribution of the patients diagnosed newly at our centre according to state. 
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Presenting features at onset of illness: 
 Table 2 shows the presenting features at onset of illness in 189 out of 198 patients. 
78(41.3%) patients had an anesthetic patch and 28(14.3%) had a deformity. 27(14.3%) had features 
of reaction.  
 
Presenting features at the time of study: 
 21.2% of consultations were for knowing the adequacy of treatment. 19.2% presented 
with a deformity and 10.1% complained of trophic ulcer. These details are shown in table 3. 
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Table 2: Presenting feature at onset of illness. 
Symptom  All patients 
     n(%) 
Newly diagnosed 
  n(%) 
Anesthetic patch(es)   78(41.3) 11(31.4) 
Deformity   28(14.3)   3(8.6) 
Trophic ulcers     5(2.6)   1(2.9) 
Erythematous patches suggestive of Type1 reaction     7(3.7)   3(8.6) 
Erythema Nodosum Leprosum   13(6.9)   4(11.4) 
Non anesthetic patches   15(7.9)   4(11.4) 
Sensory loss without patches/ paresthesias   23(12.2)   3(8.6) 
Swelling of the hands / feet     4(2.1)   1(2.9) 
Neuritis       7(3.7)   1(2.9) 
Epistaxis      3(1.6)   1(2.9) 
Infiltrations      4(2.1)   3(8.6) 
Others       2(1.1)   0 
Total  189(100) 35(100) 
 
 
 
 
 
 
Table 3: Presenting feature at the time of the study. 
Presenting features at the time of study All patients n(%) 
Opinion on treatment adequacy   42(21.2) 
Type 2 reaction   18(9.1) 
Trophic ulcer   20(10.1) 
Deformity    38(19.2) 
Sensory loss     6(3.0) 
Swelling of the hands and/ or feet/ infiltrations   10(5.1) 
Dermatological problem unrelated to leprosy     8(4) 
Paresthesias     11(5.6) 
Patch    20(10.1) 
Type 1 reaction   19(9.6) 
Others      6(3.0) 
Total  198(100) 
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History of contact: 
                       History of contact was available in 153 patients, of whom 30 patients(19.6%) gave 
history of contact with leprosy. 
 
Bacillary(BI) and morphological indices(MI) : 
                         Of the 198 patients, 16 patients did not get their skin smear test done. 
Among the rest(182), the smears were positive in 48 cases.  The mean BI in these cases was 2.98+ (± 
1.72) with  a maximum of 6+. The mean MI in these cases was 0.26% (± 0.6) with a maximum of 
2.5%.  Skin smears were available in 32 out of 35 new cases. Of these, smears were positive in 
15(46.88%) cases, the mean value in these cases was 4.25+ (±1.355) with a maximum of 6+. The 
mean MI among these cases was 0.75% (±0.865) with a maximum of  2.5%. 
 
 Disability scores: 
             Of the clinic attendees, the disability scores were as follows for 195 out of 198. 
89(45. 64 %) had no disabilities, 26(13. 33%) had grade 1 disability and 80(41.03%) had grade 2 
disability. This is shown in Fig. 5. 
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                    Figure 5: The WHO disability grades of the clinic attendees. 
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PROFILE OF THE STUDY POPULATION: 
 Out of a total of 198 patients, 81 consented for participation in interviews on 
utilization profile, activity limitation, participation restriction and mental health status.   
 
Socio-demographic profile: 
 There were 67(82.7%) males and 14(17.3%) females. This group of 81, was 
representative of the above group of 198 with respect to age, sex, religion, state, MB/PB status and 
WHO disability grades, shown in table 4. Based on occupation, the largest groups were Government 
employees and students 12(14.8%) each, followed by housewives and shopkeepers 7(8.6%) each.  
93.2 % of the study population was literate, of which 24(32.9%) were graduates. 
 
Disease characteristics: 
Duration and disease spectrum: 
 The mean duration from onset of disease to enrolment in the study was 78.82 
(±109.602) months, and the median was 36 months. Excluding a patient who had undiagnosed 
disease for 624 months, the mean was 72.01(± 91.407) months.  There were 67(82.7%) known cases 
of leprosy and 14(17.3%)newly diagnosed patients.  Among the new cases, 5(35.7%) were 
paucibacillary and 9(64.3%) were multibacillary. At the time of evaluation at our centre, 20 patients 
(24.7%) were in reaction, of which 11(13.6%) had a Type 1 reaction and 9(11.1%), a Type 2 
reaction.  Out of 79 patients, 32(40.5%) had a past history of reactions. 22(27.2%) had history of 
contact with leprosy. 
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                     Table 4:  Socio demographic and clinical data of the clinic attendees                        
                                     and  the study population. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinic 
attendees 
Study 
population  
Characteristics 
n(%) n(%) 
0- 10     4(2.0)   3(3.7) 
11- 20   13(6.6)   6(7.4) 
21- 30   61(30.8) 26(32.1) 
31- 40   52(26.3) 18(22.2) 
41- 50   32(16.2) 15(18.5) 
51- 60   20(10.1)   9(11.1) 
61- 70   13(6.6)   2(2.5) 
71- 80     2(1.0)   2(2.5) 
Age distribution 
81- 90     1(0.5)   0 
Male  162 (81.8) 67(82.7) Sex 
Female    36(18.2) 14(17.3) 
Hindu  173(87.4) 70(86.4) 
Muslim    22(11.1) 10(12.3) 
Religion  
Christian      3(1.5)   1(1.2) 
Inactive disease   83(41.9) 27(33.3) Active/ inactive 
disease Active disease 115(58.1) 54(66.7) 
New diagnoses    35(17.7) 14(17.3) 
Treated HD   36(18.2)   7(8.6) 
TTHD   13(6.6)   5(6.2) 
BTHD   68(34.3) 33(40.7) 
BBHD     5(2.5)   3(3.8) 
BLHD   25(12.6) 11(13.6) 
LLHD   34(17.2) 15(18.5) 
Diagnosis  
Pure neuritic   17(8.6)   7(8.6) 
PB   63(32.3) 28(35) Bacillary status* 
MB 132(67.7) 52(65) 
0   89(45.64) 35(43.21) 
1   26(13.33) 13(16.05) 
WHO disability 
grades** 
2   80(41.03) 33(40.74) 
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BI and MI:  
 22 out of the 81 patients had positive smears. The average BI among these cases was 
2.65+(± 1.886), with a maximum of 5.75+.  The average MI was 0.21%(± 0.569), with a maximum 
of 2%. Among the new cases, smears were positive in  5 out of 14. In these cases, the average BI 
was 4.01+(± 1.997), and the average MI was 0.72%(± 0.996). 
 
Disability grades: 
 The WHO disability grades are given in Fig. 6. The WHO grades correlated 
significantly with past history of reaction ( p=0.004), with bacillary status,  (p=0.006)   and with 
male gender(p = 0.013), shown in tables 5, 6 and 7 respectively. 
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Table 5. Comparison of WHO grades and past history of reaction. 
Past history of reactions  
No  Yes  
 
Total  
 
p value 
0 27 7 34 
1 7 5 12 
WHO  
disability  
grades 2 13 20 33 
Total  47 32 79 
0.004 
 
 
 
 
Table 6. Comparison of WHO grades and bacillary status. 
Bacillary status  
PB MB 
 
Total  
 
p value 
0 19 16 35 
1 2 10 12 
WHO  
disability  
grades 2 7 26 33 
Total  28 52 80 
0.006 
 
 
 
 
 
 
Table 7. Comparison of WHO grades and male sex. 
                    Sex   
Male  Female  
 
Total  
 
p value 
0 24 11 35 
1 12 1 13 
WHO  
disability  
grades 2 31 2 33 
Total  67 14 81 
0.013 
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Disability at onset of illness: 
                        64 out of 67 known cases were able to give details of disability at the onset of illness 
and any disabilities which developed thereafter. At the time of onset of illness, 41(64.1%) had no 
disability, 10(15.6%) had a grade 1 disability and 13(20.3%) had a grade 2 disability. Among the 41 
patients who had no disability, 3 patients developed a grade 1  and 12 patients developed a grade 2 
disability. Out of 10 patients who had a grade 1 disability at the onset of illness, 6 developed a grade 
2 disability subsequently. Out of 13 patients who had a grade 2 disability, 1 patient acquired a  new 
grade 1 disability and 3 patients, new grade 2 disabilities. At the time of  presenting to our center, 
there were 48.4%(31/64)patients with grade 2 disability. Fig. 7 depicts the disabilities at 
presentation, and the disabilities acquired during or after treatment of these 64 patients.  
 
 32(40.5 %) had a past history of reactions. 21 out of the 32 had a resultant deformity 
and data on 1 patient was not available. Among those who were deformed, there was no statistical 
significance between those who had received steroids for their reaction and those who had not( p =  
0.590).  The results were the same, even when patients with history of neuritis alone were 
considered( p = 0.509). 
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                      Figure 6: WHO disability grades of the study population. 
 
 
 
 
 
 
 
 
 
 
 
 
 
           
 
            Figure 7: Disabilities at onset of illness and disabilities acquired thereafter. 
 
 
 
 
 
 
 
 
 
 
 
 
33
40.74%
13
16.05%
35
43.21%
2
1
0
WHO disability grades
WHO grade 2 (n= 13)WHO grade 1 (n=10)WHO grade 0 (n=41)
Disabilities present at the onset of illness
50
40
30
20
10
0
D
is
ab
ili
tie
s 
ac
qu
ire
d 
du
rin
g 
or
 a
fte
r t
re
at
m
en
t
3
4.69%
6
9.38%
12
18.75%
1
1.56%
3
4.69%
9
14.06%4
6.25%
26
40.62%
2
1
0
Newly acquired
disabilities, WHO grade
 51
UTILIZATION PROFILE: 
 
Delay: 
                       64 out of 81 patients were able to recollect data regarding delay between onset of 
symptoms and starting any antileprosy treatment. Among these 29(45.3%) had a delay upto 6 
months and 35(54.7%) had a delay equal to or more than 7 months. Complete data with regard to 
patient and health care system related delays were available in 58 out of the 64 patients. Among 
these,  the patient with an outlier value of 624 months between presentation and treatment was 
excluded. In this group the distribution of delays are shown in table 9. The various correlates of 
delay are discussed below and shown in table 10.  
♦ Age upto 35 years and more than 35 years: 
The overall delay was longer in patients upto 35 years as compared to those above 35 years. 
♦ Gender differences: 
The average delay from onset of symptoms to presentation was 7.33 months in males and 10.32 
months in females. 
♦ Differences in delay between Tamil Nadu and West Bengal: 
There was a longer health care system delay in patients from West Bengal. 
♦ Disability: 
The delays were longer in patients who did not have a disability as  compared to those with 
disabilities. 
♦ Pure Neuritic leprosy: 
The delay was 11 months in patients with pure neural disease. 
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              Table 8: Reason for seeking care at our centre. 
Reason for seeking care at our centre n(%) 
Second opinion 20(25) 
Dissatisfaction with previous treatment 17(21.3) 
Reputation    7(8.8) 
Other medical/ surgical illness/ dermatological 
 problem not related to leprosy 
14(17.5) 
New deformity   3(3.8) 
Persistent reaction   2(2.5) 
Primary care   4(5) 
Trophic ulcers   5(6.3) 
Correction of deformity    2(2.5) 
Referral   6(7.5) 
Total 80(100) 
 
 
 
   Table 9: Delay characteristics: 
 
Delay in months  Mean  Median  Range  Std. deviation
From onset of symptoms to presentation
(patient related delay) 
  7.9 3   48 10.46 
From presentation to diagnosis   3.82 0   60 10.41 
From diagnosis to starting treatment   1.61 0   72   9.60 
From presentation to starting treatment 
(health care system delay) 
  5.44 0 108 16.77 
From onset of symptoms to starti
treatment 
13.34 7 109 19.68 
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♦ Bacillary status: 
Paucibacillary patients had a longer health care system delay. 
♦ Past history of reactions: 
The overall delay was lesser among patients who had a past history of reaction.  
♦ Use of alternative medicine:  
17 of our patients had used alternative medicine and homeopathy was the most popular type. The 
health care system delay was longer in those who had taken alternative medicine. 
♦ There was no correlation with  levels of education (p= 0.553). 
♦The number of doctors sought by the patients ranged from 1- 9.  The factor of seeking more 
physicians was not associated with a longer delay(ρ = 0.082). 
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Table 10. Correlates of delay. 
Symptom  
onset & 
Presentation 
 
Presentation 
& diagnosis 
 
Diagnosis &  
 start of  
treatment 
 
Presentation 
& start of 
treatment 
Overall delay  
 
 
Mean* S.D Mean* S.D Mean* S.D Mean* S.D Mean* S.D 
p value 
 for  
differences in  
overall delays 
<35 y(35) 
7.94 11.643 4.06 8.850 2.31 12.165 6.38 18.991 14.31 20.907 
Age  
 
>35 y(22) 
7.85 8.485 3.44 12.733 .50 1.946 3.94 12.743 11.80 17.917 
 
 
 
0.642 
 
M    (46) 7.33 10.856 2.81 6.969 2.00 10.667 4.81 16.341 12.14 18.724 
Sex  
 
F     (11) 
10.32 8.591 8.07 19.083 .00 .000 8.07 19.083 18.39 23.592 
 
 
0.349 
Tamil 
Nadu(16) 10.64 12.341 .27 .998 .00 .000 .27 .998 10.91 12.239 
State  
West(26) 
Bengal 8.63 11.038 5.96 14.061 3.46 14.126 9.42 23.735 18.05 26.124 
 
 
0.312 
No (26) 9.03 10.963 5.20 14.146 3.12 14.160 8.32 23.964 17.35 26.008 Disability
Yes(31) 6.96 10.093 2.67 5.714 .35 1.082 3.02 5.773 9.98 11.565 
 
 
0.190 
No (52) 8.20 10.837 3.71 10.833 1.65 10.035 5.37 17.528 13.57 20.566 
Pure  
Neuritic  
leprosy 
Yes  (5) 4.80 4.438 5.00 4.472 1.20 2.168 6.20 4.494 11.00 4.690 
 
 
0.783  
PB (20) 7.99 11.737 7.05 15.920 4.30 16.092 11.35 26.889 19.34 29.208 
Bacillary 
status 
MB(36) 7.41 9.615 2.14 5.161 .17 .609 2.31 5.164 9.72 10.920 
 
 
0.081 
No (32) 9.55 11.620 5.16 13.272 2.72 12.769 7.88 21.881 17.44 24.512 
Past 
history 
of  
 reactions
Yes(24) 5.78 8.688 2.20 4.553 .21 .721 2.41 4.515 8.19 8.933 
 
 
 
0.056 
No (38) 7.76 11.038 1.01 2.616 .39 1.552 1.41 2.967 9.17 10.897 
Used 
alternative
medicine 
Yes(13)  9.85 10.869 11.69 18.441 5.92 19.902 17.62 31.947 27.46 33.346 
 
 
0.074 
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Number of physicians consulted:  
 76 patients were able to give the details of the number of physicians they 
consulted for treatment, before coming to our centre. The mean number of doctors consulted was 
2.5(± 1.822), median was 2, mode, 1 and the maximum was 9. Among the 14 newly diagnosed 
patients, 6 patients presented to our centre for the first time after noticing the symptoms. In the 
other 8, the average number of visits before being diagnosed was 1.25. Only one of these 8 
patients had used Government health care services. Of the 6 patients who presented first at our 
centre, 3(50%) were contacts of patients with leprosy and all three presented with a patch. Fig. 8 
shows the number of physicians consulted. The number of doctors was more in patients with past 
history of reactions  (p < 0.001), with multibacillary disease (p= 0.025) and with use of 
alternative medicine (p= 0.001). Among the states, patients from Tamil Nadu consulted an 
average of 1.32(± 0.885) physicians, those from West Bengal, an average of 2.71(± 1.707), and 
all other states put together, 3.26(± 2.207) were consulted. The differences were significant(p = 
0.002). This is shown in Fig. 9.  There were no significant differences between duration of 
disease and the number of physicians consulted (p = 0.384), or gender of the patient (p = 0.054). 
 
Defaulting: 
 Of the 67 known cases, 7 had defaulted at some point of treatment.  1 patient 
defaulted after coming to know of her diagnosis and was not on any treatment at the time of the 
study, the rest (6) had restarted treatment. 
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             Figure 8: Number of physicians consulted by the patient. 
 
 
 
                
 
 
 
 
 
 
 
 
 
 
 
 
 
                      Figure 9: Number of physicians - state wise. 
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Prior treatment:  
 59 patients had complete details of previous treatment. 1 had defaulted after 
coming to know of the diagnosis and was not on any treatment, 1 was diagnosed, but not treated 
and the rest of the patients could not recollect exact details. 35/ 59 had taken only WHO MDT, 
15/ 59 had other regimens of antileprosy treatment and 9/ 59 had taken both, shown in Fig.10. 
The average duration of antileprosy treatment was 28.28 months, of which the average duration 
of MDT was 11.4 months and that of other antileprosy treatment regimens was 16.86 months. 
 
Awareness about diagnosis: 
 Among  the known cases, 7(10.6%) patients were not aware of their diagnosis, even 
though 5 of them had received MDT and 4 could definitely identify the blister packs. 59(89.4%) 
were aware of their diagnosis.  38(64.4%) out of 59 patients were able to identify blister packs. 
 
Symptoms after release from treatment (RFT): 
 There were 29 patients who had been released from treatment, earlier. Details of  
presence or absence of treatment after RFT were available in 28. Among these 6(21.4%) had no 
complaints post RFT, the rest (78.6%) had complaints that necessitated a physician’s care after RFT.  
7 of these were restarted on treatment for leprosy. Their reasons for seeking a physician are shown in 
table 11. All patients who had sensory loss were not aware of the possible irreversible nature of their 
disability. 
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                                                   Figure 10: Treatment details. 
 
 
 
              
 
 
 
 
 
 
 
 
 
 
 
 
 
                   Table 11: Reasons for seeking care after release from treatment 
  
Reasons for seeking care  (n) % 
Persistent sensory loss   6 21.4 
Persistent motor weakness   4 14.2 
Reactions     5 17.9 
Trophic ulcers/ callosities   5 17.9 
New patches   1   3.6 
Generalised malaise    1   3.6 
Total  22 78.6 
 
 
 
 
81 - Study population
67- Known cases 
       of    leprosy
14 - New cases
2 – Never started  
      antileprosy drugs 
6 - Unable to 
      recollect details
59 - Treatment  
           details  available
35 – WHO  MDT only
15 –  Other regimens of  
  antileprosy treatment only
 9 - Both
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Cost analysis: 
 Out of 81 patients the details of economic impact was available in 62. Of these, 
complete details regarding the direct and indirect costs were available in 60 patients and are 
shown in table 12. 
 
Loss or change of job: 
 12(19.4 %) were forced to lose or change their jobs.  Their productivity losses are 
shown under indirect costs, in table 12. 
 
 The differences in expenditure by gender, state, bacillary status, disease activity 
are shown in table 13. 
 
 Patients spent an average of 20.05(± 29.88)% of their annual earnings on health 
care. The median was 6.75%, and the maximum spent was 128.53% of the annual income. 
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Table 12: Costs over the past 1 year. 
 
Cost In Rupees Direct cost Indirect cost Total cost 
Mean 4309.52 4748.89 7871.18 
Median  2112.50 0 2720.00 
Std. deviation 7906.986 12491.536 16173.074 
Minimum 0 0 0 
Maximum  44400 63900 92400 
 
 
 
Table 13:  Comparisons of cost based on  gender, states, bacillary status and activity. 
 
Direct cost (Rs.) Indirect  cost (Rs.) Total  cost (Rs.)   
Mean  S.D Mean  S.D Mean  S.D 
p value 
for 
difference
in total 
costs 
Male  
 3652.06 6125.066 3013.46 9924.539 6665.52 12320.543
Sex 
Female 
 8583.00 15150.619 7125.00 16813.579 15708.00 31901.706
0.453 
TamilNadu 
 3312.69 5006.306 5792.31 17639.466 9105.00 21077.025
State 
West 
Bengal 4188.06 8005.281 3762.50 9727.837 7950.56 16639.230
0.846 
MB 
 3567.09 9651.162 3000.00 10757.057 6567.09 19733.447
Bacillary 
status* 
 PB 
 4786.35 6892.846 3991.89 11380.939 8778.24 14106.104
0.619 
Inactive   
 3785.71 9873.356 4571.43 11834.574 8357.14 20488.617
Disease 
activity 
Active  
 4591.56 6747.666 3017.95 10619.393 7609.51 13600.728
0.866 
*n = 59 
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                                        Figure 11: Participation scale. 
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ASSESSMENT OF PARTICIPATION RESTRICTION, ACTIVITY LIMITATION AND 
MENTAL HEALTH STATUS  
 
P scale: 
 The P scale was performed on 61 patients. The mean score was 4.95(±6.46) and 
median was 3. The minimum score was 0 and maximum was 28. Using the P scale, 8 patients 
had a mild restriction of participation and 2 had a moderate restriction and 51 had no restriction, 
shown in Fig. 11. 
 
 The P scale score was higher in patients who had to change or lose their 
jobs(p=.012), and in patients who gave a history of suicidal tendencies ( p = 0.039).  
 
 There was no relationship of the P scale with regard to age (r = -0.22) or gender (p 
= 0.084), education (p = 0.293), duration of disease(r = -0.010), state of residence (p = 0.878), 
WHO disability grades (p = 0.364), past history of reaction (p=0.826) or present reactional state 
(p = 0.137) or type of housing (p = 0.079). 
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SALSA: 
 The SALSA scale was done on 63 patients. The median score was 22, mean was 
24.30(± 6.26), with a minimum of 19 and a maximum of 52. The safety awareness score 
ranged from 0 to 5, with a mean of 0.75 (± 1.307). The awareness score was not more among 
patients with a higher level of literacy (ρ = - 0.097) or longer duration of disease (ρ = - 0.015). 
SALSA scores were higher with higher grades on the WHO disability scales (p=0.008) using 
the Kruskal – Wallis test. 
 
 There were no significant correlations between the age (r = 0.022), gender (p = 
0.595), education (0.476), type of housing (p = 0.841), or a higher number of physician 
consultations (ρ = 0.095). 
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Mental health impairment: 
GHQ 12: 
 The GHQ 12 was applied to 55 patients. The median value was 3, mean was 
3.45(± 3.63), the minimum score was 0 and the maximum 12. 4 patients scored 12. Using the 
GHQ 12,  28(50.9 %) cases were found to be depressed, shown in Fig. 12.  
 
 There were significant correlations between the GHQ 12 and a higher number of 
physician consultations (p = 0.012, r = 0.354). There were no significant correlations between 
the GHQ 12 and age (r = -0.093), sex (p = 0.406), present reactional state (p = 0.073), education 
(p = 0.250), loss or change of job (p = 0.123), socioeconomic status by housing (p = 0.082), 
knowledge of disease (p = 0.490) or with increasing disability (p =0.667). 
 
ICD 10 primary care criteria for depression: 
 Using the ICD 10 criteria, 6 out of 50 patients (Fig. 13) were diagnosed to have 
depression, all of whom had depression on screening using the GHQ 12, shown in table 14. The 
correlation between the GHQ 12 and the ICD criteria was significant           (r = 0.355). The ICD 
criteria showed no correlations with increasing disability.  22.2% of patients in our study had 
suicidal ideation or acts. 
 
GHQ 12 & ICD 10: 
 Against the ICD 10 criteria for confirming depression, the GHQ 12 had a 
sensitivity of 100%, though the specificity was only 54.5%. 
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                              Figure 12: Depression according to GHQ 12. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                            Figure 13: Cases of depression according to the ICD criteria. 
 
 
 
 
 
 
 
               
 
 
 
 
 
             Table 14: Comparison of GHQ 12 and ICD 10 criteria (p = 0.021) 
Depression by ICD 10 criteria  
No  Yes  
Total  
No  24 0 24 Depression 
by GHQ 12 Yes  20 6 26 
Total  44 6 50 
28
50.91%
27
49.09%
YES
NO
Depression as
screened by the
GHQ 12
6
12.0%
44
88.0%
YES
NO
Cases of depression as
diagnosed by the ICD-
10 criteria
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Correlations of the P scale, the SALSA, and the GHQ 12: 
 Out of 63 patients, 54 had complete details regarding the P scale, SALSA scale 
and the GHQ 12. 
 
P scale and the GHQ 12: 
 The P scale score had significant correlations with cases of depression as 
diagnosed by the GHQ 12, (r = 0.599, p < 0.001), shown in Fig.14.  
 
P scale and the SALSA scale: 
 There is a linear correlation between the P and the SALSA scales,  
(r = 0.43, p = 0.003), shown in Fig. 15. 
 
SALSA and GHQ 12: 
 The SALSA did not correlate with the GHQ 12 (r = -0.149) or with the ICD 
criteria (r  = - 0.042). 
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                        Figure14: Correlations between the P scale and the GHQ 12. 
 
 
    
 
 
 
             
 
                                                             
 
                                                                                           
 
  
                           
                      
 
  
                          
 
           
   
 
                    
 
 
                         Figure 15: Correlations between the P scale and the SALSA. 
                 
 
 
 
 
 
 
 
 
 
50403020
SALSA - Total Scores
30
25
20
15
10
5
0
Pa
rt
ic
ip
at
io
n 
Sc
al
e 
- T
ot
al
 S
co
re
s
121086420
GHQ 12 Total scores
25
20
15
10
5
0
Pa
rt
ic
ip
at
io
n 
Sc
al
e 
- T
ot
al
 S
co
re
s
 69
                                                     DISCUSSION 
 
 Leprosy is on the decline according to national and international statistics. 
Leprosy services are fully operational under the general health care services and free and  
unrestricted access to medical care has been promised. However, the needs as felt by the patients 
may not always be captured by incidence or prevalence rates. In order to cater to the patients as 
best as possible, it is necessary to know the health care utilization of the patients and their needs 
and wants which  influence that profile. In fulfilling the commitment towards early case 
detection and prompt treatment, we need to know the delays that come in the way of  the above 
goals.  
 
Socio demographic profile: 
 In our study, a total of 198  patients with leprosy accessed our centre, during the 
study period of 18 months. This figure included both active and inactive cases.  Of these, only 
18.2 %( as against the national prevalence of 35.78%)4, 5 are females, and this discrepancy 
becomes more obvious when active cases alone are considered. This under representation of 
females could  probably be attributed to the distance that needs to be travelled, especially in the 
case of patients other than those from TamilNadu.  This is plausible considering that 47.98% of 
the patients hail from West Bengal which is 1813 km away. Overall we had patients coming to 
us from 9 states other than Tamil Nadu. We had only 6 patients aged  less than 15 years,  also a 
possibility arising out of the above situation. 
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Disease characteristics: 
 Patches on the skin were the first noticed symptom in  42.8% of the  cases  newly 
diagnosed at our centre (anesthetic in 31.4%), and other common presentations of  leprosy like 
trophic ulcers, deformity and ENL made up 22.9% . Overall,  65.7% of  our new cases  could 
have been easily picked up by a trained health worker at the primary health centre level. This 
prompts two conclusions – either the masses are not adequately  aware of the local availability of 
leprosy services, in which case the component of awareness has to be strengthened , or  cases are 
being missed at the primary level, which calls for better training and orientation programmes for 
all health workers. 
 
 Patches and nerve involvements are the only diagnostic criteria, recommended by 
the WHO.1 Skin smears are not routinely done. However, we found that among our newly 
diagnosed patients, 46.88% were smear positive, with an average bacillary index of 4.25 and a 
maximum of 6. The proportion of MB cases among the newly diagnosed was 71.4%, higher than 
the national average of 45.83%.5 Considering both the above factors, skin smear testing is 
necessary in identifying cases which may have atypical presentations, but which nevertheless 
disseminate infection.  
 
 The national rate for visible deformity is 1.59%, though the percentage of people 
with grade 2 deformity in our study, was as high as 41.03%. about twice that  found by Kumar et 
al52 in a tertiary care centre in Agra and by Pimentel in Brazil.45 This could be due to the fact that 
established reconstructive services, (Dr Paul Brand Centre for reconstructive surgery) are 
available at our centre,  which probably influenced the client's choice. 
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 Among the known cases of leprosy, the disability rates had risen from 20.3% to 
48.4%, which was in stark contrast to a study from Brazil, in which the disability rates actually 
decreased through treatment and follow up.45 This probably reflects on the level of efficacy of 
prevention of disability measure available to patients. Males had more deformities compared to 
females(p = 0.013) in keeping with earlier studies.52, 64 
 
Utilization profile: 
 We considered delays under the following headings: from onset of symptoms to 
presentation or the patient related delay, from presentation to diagnosis, and from diagnosis to 
treatment, both of which together would give the health care system  related delay.  The delay to 
presentation  in our study was 7.9 months, slightly more than the recommended maximum of 6 
months.26, 43  The overall delay was 13.34 months with a health care system related delay of 5.44 
months, lesser than  a study from Nigeria.53 45.3% had a delay less than 6 months, which is 
shorter when compared to earlier values from  India and from other endemic countries.26, 45, 51 
The use of alternative medicine was associated with a longer health care system delay( 17.62 
months in those who  used alternative medicine as against 1.41 months in those who did not); 
this was in accordance with available data.41 Females  had a longer delay than males, similar to 
studies from West Bengal, Bangladesh and Maharashtra,41, 48  though a recent study from Delhi 
showed otherwise.52 The delay was  lesser in patients with past history of reactions,  this was in 
keeping with the risk factors suggested by PG Nicholls et al. 43  The overall delay was actually  
lesser in patients with pure neuritic disease,  which  in fact, was considered a risk factor for 
delay, according to this study.43 In our study, when comparing  patients aged more than 35 with 
those aged upto 35 years, though the time to presentation was similar, the health care system 
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delay was more in the latter group. This resulted in a longer overall delay disagreeing with 
available data,41 though the difference was not significant. 
 
 In our study the delay was greater in paucibacillary patients as compared to 
multibacillary cases, disagreeing with earlier studies.26, 52 The difference here was attributable 
primarily to the health care aspect of the delay in our study, i.e. failure to diagnose paucibacillary 
cases early.   
 
 Patients with disabilities had less delays than those without disabilities, differing 
from earlier studies.43 This finding is encouraging considering that early presentation is 
desirable, especially if patients already have a nerve function impairment. However, this could 
also mean that cases with subtle presentations are being missed.  
 
 We also found that the mean delays were longer in patients from West Bengal 
(18.05 months) as compared to those from Tamil Nadu (10.91 months).  The difference in delay 
was attributed primarily to the health care component (9.42 months among West Bengal cases 
and only 0.27 from Tamil Nadu). 
 
 We opine that, rather than giving a blanket value to account for the time between 
onset of symptoms to starting treatment,  it would be preferable to break it up into smaller 
components. This will give us an idea of where exactly the problem lies, as in the above two 
instances where the  health care delay was responsible for the difference in the delays.  For, once 
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the problem is identified , resources can be preferentially diverted to solve it. Salvaging available 
resources is especially important in the context of integration. 
 
 The average number of physicians consulted was 2.5 (± 1.822), which was 
remarkably similar to a study done 25 years ago. However, there were no associations with male 
sex or with duration of disease.46 Newly diagnosed patients among the study population, had to 
visit an average of 1.25 physicians before a  diagnosis was made. Studies from Nigeria state a 
value of 2.7.53 We compared the states under 3 headings as Tamil Nadu, West Bengal and others. 
The number of physicians contacted was highest in patients from the third group(3.26±2.207) 
and least among cases from Tamil Nadu(1.32±0.885) while  patients from West Bengal had 
visited  an average of 2.71 (± 1.707) physicians( p = 0.002). This could be because 68.42% of 
patients from TamilNadu had seen no other or only a single other physician before coming to our 
centre.  
 
 There are no studies looking at the reasons why a patient would continue to seek 
medical help even after being declared cured and released from treatment. In our study we found 
that 35.8% of our patients had trophic ulcers and reactions, both of which need quality medical 
care, including hospitalization if necessary. The case burden of 20.7% who presented with 
persistent sensory loss could have been avoided if patients had been adequately counseled 
regarding the nature of their impairment. 
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Economic losses: 
 Our patients had spent an average of 20.05% of their annual income on health 
care for leprosy, with the maximum being 128.53% .  
 
 We found that 12(19.4%) of our patients  were forced to lose their jobs or change 
over to another, less demanding  and probably lesser paying job.  This was  less than earlier 
studies from Nigeria 49and Tamil Nadu.73, 75  This could  probably be a result of reduction both in 
stigma and in case load, considering that both the above studies were published 2 decades ago.  
 
Participation restriction:  
 The P scale was developed  primarily  to assess the impact of rehabilitation 
programmes.15 We used it as a tool in a cross sectional analysis to know the existing level of 
participation limitation in the community in the context of integration.74   We found that 
10(16.43%) of our patients faced participation restrictions, of which 2(3.3%) faced moderate 
restriction. 70 % of patients, who faced any restriction according to the P scale interpretation, 
had  given the maximum score to at least one of the first       3 questions in the scale. These 
questions explored the work and productivity aspects of participation. Not surprisingly, there was 
a significant correlation(p = 0.012) among patients who had lost their job or changed over to 
other jobs.  We feel that participation restriction and depression can be a cause as well as a 
consequence of each other, the P scale scores were found to be higher in patients with depression 
as measured by the  GHQ 12. Further studies with more patients will be required to evaluate the 
inter relationship between the two parameters. 
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 Evaluating the  level of  participation restriction in  relation to the level of  
activity limitation, we found that the P and the SALSA scales correlated with each other. In view 
of this, it would be a good idea to administer both these scales together, while evaluating the 
efficacy of rehabilitation programmes.  
 
 However, since there is a paucity of data, we feel that further studies using larger 
populations should be done, before advocating this scale for use in a clinic based setting. 
 
Activity limitation: 
 The SALSA scale was developed as screening measure for health care workers to 
detect activity limitation.14  In our study , the activity limitation was found to increase with the 
disability grades( p = 0.008), as has been described in the original study.14  We found no 
correlations with age as has been mentioned in the above study.  Though we have used this study 
cross-sectionally, we feel that this scale could be of more use in longitudinal studies  along with 
measurements of the EHF sum  scores to assess the efficacy of prevention of disability 
programmes.  
 
 From our experience, we feel that the use of  this scale has its principal advantage 
in providing the primary care physician with insights into what the patients does and does not 
know, on prevention of disability. At the same time, it provides a check list to make sure that 
relevant aspects with  regard to prevention of disability(POD), have been discussed with the 
patient. This justifies our rationale in supporting  its use in a busy, clinic based setting where it is 
possible to miss out on some detail only to have the patient return with a burn or an ulcer. Once 
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again, the efficacy of using this scale for health education can be confirmed only with  
longitudinal studies. 
 
Mental health impairment: 
                         We found 50.9% of our patients to be depressed using the GHQ 12 , with a cut off 
of 2/3 as has been advocated by Goldberg et al.114 However, only 6 of these patients, were  
confirmed to have depression using the ICD 10 criteria.  Using this cut off, the GHQ 12 was 
found to have a similar sensitivity in our study as has been found in an earlier study in culturally 
comparable population.114   22.2%  of patients in our study were found to have had suicidal 
thoughts or acts. This was higher compared to the 18.5% reported from Ethiopia.111  Surprisingly 
the mental health impairment as determined by the GHQ 12 and the ICD 10 criteria did not 
increase with higher disability grades  as has been proved in earlier studies.98, 109-112, 115 We 
suggest the use of  a better tool with more specificity for evaluation of the mental health 
impairment. Another option would be  to use 2 scales, one for screening and another with higher 
specificity for confirmation, as has been used here. 
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                                                     LIMITATIONS OF THE STUDY 
 
1. Patients were required to spend considerable time (45- 60min) for the assessment. Owing to 
which, only 81 of the available 198 patients, consented for participating in the questionnaires 
related to activity and participation limitations and mental health status. Also, owing to a 
language barrier, patients who did not have a working knowledge of  any one of  the languages 
used ( English, Tamil, Hindi and Bengali) could not participate in the above assessments. This 
limited the number of patients available for evaluation of these parameters. 
2. The estimated cost of care represents only a fraction of capital spent, the lifetime costs are not 
captured. 
3. Ours being a cross sectional study, we were unable to evaluate the potential of the SALSA 
scale as a tool in health education for prevention of disability. 
4. Since most of the information used in our study were based on patients' recounting of past 
events, recall bias is a factor to be considered. 
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                                                  CONCLUSIONS 
 
1. Even after completion of integration, and direct and easy availability of leprosy services at the 
primary healthy centre  level, we found 35(17.7%)  patients who were first diagnosed at a tertiary 
level hospital. 28.6% presented with anesthetic patches, which could have been easily identified 
by a health worker. Skin smears should be considered in clinically suspicious cases. 
2. 81.82 % of patients were from outside Tamil Nadu.  Patients  from West Bengal constituted 
the majority having to travel 1813 km to reach Vellore. 
3. The grade 2 deformity rates were high, 40.74%.The percentage of people with grade 2 
disability had risen from 20.3% at the time of onset of illness to 48.4% at the time of study. 
4. The average delay from presentation to starting  treatment was 13.1 months. The delay to 
presentation was longer in females as compared to males. The overall delay was lesser in people 
who had had reactions than in those without a past history of reactions. Newly diagnosed patients 
had consulted an average of 1.25 physicians before a diagnosis could be made. 74. 6% of 
patients had received MDT for their disease. It would be better to consider delays under 4 
headings as follows: delay between onset of symptoms and presentation, delay between 
presentation to diagnosis, delay between  diagnosis and starting treatment. The latter two 
summed up together would give the health care delay and all three components could be added 
up to give the overall delay 
. 
6. 19.4% had to lose  their job  or  change over to other jobs.    20.05% of   patients' annual 
earnings was spent for  their health care. 
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7. The P scale  found that 16.43% of patients had participation limitations. Patients who had to 
change or lose their job scored higher than those who did not have to. The P scale also correlated 
with the patient's mental health status and the SALSA scores. 
8. The SALSA scores increased with increasing grades on the WHO disability grading. When 
used in a clinic based setting the SALSA has a role in educating the patient on  prevention of 
disability. 
9. Using the GHQ 12 more than 50 % were found to depressed. However, only 12% were 
confirmed to have depression using the ICD 10. The sensitivity of the GHQ 12 as a screening 
test was found to be 100%, even though its specificity was only 54.5%. 
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                                                      SUMMARY  
 
A cross sectional study was done on the socio-demographic and clinical profile of patients with 
leprosy attending the out patient clinic, Department of Dermatology, Venereology and Leprosy, 
Christian Medical College, Vellore. A total of 198 patients were assessed of which 81 consented 
and were enrolled for detailed assessment of utilization profile, activity and participation 
limitations using the SALSA and the P scales respectively, and mental health status using the 
GHQ 12 and the ICD  10 criteria for depression. The majority of patients were from West 
Bengal(47.98%).  35(17.7%) patients were first diagnosed to have leprosy in our centre and 
71.4% of these were multibacillary.  The proportion of patients with impairments was high, with 
grade 1 disability of  13.33% and grade 2 disability of 41.03%.  20.3%(13/64) of patients had a 
grade 2 deformity  at onset of illness, though at the time of study this was a high as 48.4%. The 
average patient related delay was 7.9 months and the average health care system related delay 
was 5.44 months, the overall delay 13.1 months. Patients with reactions in the past had a shorter 
delay. The mean  number of physicians consulted was 2.5, though the highest value was 9. New 
patients consulted an average of 1.25 physicians before  a diagnosis was made. 10.6% of the 
known cases of leprosy were not aware of their diagnosis. 10.45% had defaulted sometime 
during the course of their illness.  74.6% of patients had received WHO MDT, either from 
private or from Government centres. 79.3% of patients released from treatment presented 
themselves for "care after cure", the primary cause being persistent sensory loss. None of them 
were aware of the prognosis of their sensory loss. The mean total medical costs for the previous 
1 year were Rs. 7871.18.  19.4% were forced to lose/ change their jobs. The P scale was used to 
assess participation limitation and it was found that 8(13.1%) patients had a mild restriction and 
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2(3.3%) had a moderate restriction. The P scale correlated with the mental health status and with 
the SALSA scores. The mean SALSA scores were 24.30(±6.26). The SALSA scores increased 
with increasing disability. 50.9% of cases were found to be depressed using the GHQ 12. When 
compared with the ICD 10 criteria for confirmation of depression, the GHQ 12 had a sensitivity 
of 100%, though a specificity of only 54.5%. 
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Annexure: 
1. A. Proforma for the clinic attendees. 
Name:                               
Age:          
Gender:             M/ F              
Hospital No. 
State: 
Religion: Hindu/ Muslim/ Christian/ others 
Duration of illness: 
Known case of leprosy:            Yes/ No 
Presenting symptom at onset of illness: 
Presenting feature at the time of study: 
Diagnosis:                                    
MB/ PB:                            
Active/ Inactive: 
Bacillary Index:                                               Morphological Index: 
WHO disability grades: 
                                           E- 
                                           H- 
                                           F- 
Contact with leprosy: Yes/ No 
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B. Proforma for the study population. 
Name: 
Age:          
Gender:             M/ F              
Hospital No: 
State: 
Religion: Hindu/ Muslim/ Christian/ others  
Education:  Illiterate/ Primary/ High School/ Graduate 
Occupation: 
Housing :             kachcha/ kachcha pucca/ pucca 
Presenting symptom at onset of illness: 
Presenting feature at the time of study: 
Diagnosis:                                    
MB/ PB:                            
Active/ Inactive: 
Bacillary Index:                                               Morphological Index: 
In reaction:                                  No / type 1/ type 2 
Deformity at onset:    Yes/ No                                    If yes, Grade: 
Developed any deformity thereafter: Yes/ No            If Yes, Grade: 
WHO disability grades: 
                                           E- 
                                           H- 
                                           F- 
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Contact with leprosy: Yes/ No 
Past history of reactions:             Yes/ No 
                                                     If Yes, any steroids prescribed?            Yes/ No 
                                                     Reaction caused a deformity?                Yes/ No 
Past neuritis:             Yes/ No 
Delays: 
Approximate date of noticing first symptom: 
Date of first consultation: 
Date of diagnosis: 
Date of starting treatment: 
Delay between onset of symptom and presentation: 
Delay between presentation and diagnosis: 
Delay between diagnosis and starting any antileprosy treatment: 
Delay attributable to the health care system: 
Overall delay: 
Health care systems used:                                         
Government :                     PHC/ Outreach clinic/ Taluk/ Dist. Headquarters/Medical college 
Number of physician consultations: 
Private :                              General Practitioner/ Dermatologist/ Private Hospital 
Number of physician consultations: 
Alternative Medicine:        Native medicine/ Homeopathy/ Ayurveda/ Siddha/ Others 
Number of physician consultations: 
Total number of   physicians consulted: 
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Treatment details: 
Able to identify Blister Pack:             Yes/ No 
WHO MDT:                                       Yes/ No (Duration) 
Other antileprosy regimens:               Yes/ No (Duration) 
Defaulting:                                          Yes/ No 
Released from treatment(RFT):          Yes/ No/ Not applicable 
                                                             If Yes, symptoms after RFT 
Whether continuing antileprosy medicines even after RFT:Yes/No 
Reason for seeking care at our centre: 
Knows about the diagnosis: Yes/ No 
 
Economic losses: 
Income per annum: 
Had to change / lose job:                   Yes/ No 
                                                            If Yes, income lost over the last 1 year  : Rs. 
Direct Medical  Cost over the last 1 year: 
                                                            Consultation 
                                                             Medicine 
                                                             Investigation 
                                                             Procedure 
Direct Non Medical Costs over the last 1 year:                      For Patient,  Care giver 
                                                              Travel 
                                                               Food 
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                                                               Stay                  
                                                               Others          
Total Medical Costs over the last 1 year: 
                            
Total Costs for the past 1 year: 
 
                                  
3. P scale and translations  in folder 2. 
4. SALSA scale and translations in folder 2. 
5. GHQ 12 and translations in folder 2. 
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6. ICD 10 Primary care criteria for depression. 
Mandatory criteria: 
1. Low or sad mood 
2. Loss of interest or pleasure 
At least 2 of the following additional criteria: 
1. Disturbed sleep 
2. Disturbed appetite 
3. Poor concentration 
4. Suicidal thoughts or acts 
5. Guilt or loss of self-confidence 
6. Fatigue or loss of energy or decreased libido 
7. Agitation or slowing of movement or speech 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 103
7.  Master charts with glossary. 
 
 
Master chart 1 – Clinic Attendees 
 
Master chart 2 –Study population 
 
For Master Chart 1,  
 
Durn(m)                Duration in months 
Active/in               Active or Inactive disease 
Diagnosis              Diagnosis 
PB/MB                  Paucibacillary/ Multibacillary 
In Reaction           Whether the patient was in reaction at the time of study 
E                           Eyes Disability Grade 
H                           Hands Disability Grade 
F                            Feet Disability Grade 
WHOdis                WHO disability grades  
Presnow                 Presenting feature at the time of study 
Contact                  History of contact  
BI                          Bacillary Index 
MI                         Morphological Index 
 
For Master Chart 2, 
 
Housing                Type of house, the patient lives in 
Knows diag          Whether patient knows his diagnosis 
Durn(m)                Duration in months 
Active/in               Active or Inactive disease 
Diagnosis              Diagnosis 
PB/MB                  Paucibacillary/ Multibacillary 
In Reaction           Whether the patient was in reaction at the time of study 
Disblonset             Disabilities at the onset of illness according to WHO grades 
Develdis                Disabilities developed therafter according to WHO grades 
E                           Eyes Disability Grade 
H                           Hands Disability Grade 
F                            Feet Disability Grade 
WHOdis                WHO disability grades 
Past Rx                  Whether patient had treatment in the past. 
Durn(m) Rx           Duration of treatment in months 
DurnWHO             Duration of WHO MDT in months 
Durnother              Duration of other antileprosy regimens 
Pastreacn               Past history of reaction 
Steroids                Whether given steroids at the time of reaction 
Deformed             Did the reaction cause deformity? 
Blisterpac             Able to identify blister packs? 
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RFT                      Released from Treatment 
No. Doc                Number of physicians consulted by the patients 
Govt util               Utilisation Of Government services 
Pvt util                 Utilisation Of Private services 
Alter Med            Use Of Alternative Medicine 
Reason                 Reason for seeking care at our centre 
Del Pres               Delay between onset of symptom to presentation 
Del Diag              Delay between presentation and diagnosis 
Del treat               Delay between diagnosis and starting antileprosy treatment 
Overall Del          Overall Delay 
HCS del               Health Care System Delay 
Job change           Whether patient had to change/ lose his/her job 
IDC                       Indirect  Costs 
DMC                    Direct Medical Costs 
DNMC                 Direct Non Medical Costs 
TMC                    Total Medical Costs 
Total                    Total costs over the past 1 year 
Ann. Inc               Income / year 
 % Spent              Total Costs/ Income per year 
GHQ score           GHQ 12 total score 
GHQ case            Depression as screened by the GHQ 12 
ICD case              Cases of depression as diagnosed by the ICD- 10 criteria 
Suicidal                  Suicidal thoughts or acts 
P Scale                   Participation Scale - Total Scores 
PS interpr               Interpretation of the P scale scores 
SALSA                   SALSA - Total Scores 
Safeawar                 Safety Awareness Scores 
 
 
 
 
 
 
 
 
 
